In addition, a national cancer database study of bGBM [4] showed that MGMT promoter methylation, a known favorable prognostic and predictive factor in GBM, was in fact more prevalent in bGBM patients (47.1% vs. 40.2%). This evidence concerns the gene MGMT and cancer.